Literature DB >> 28947175

Primum non nocere: Are we ready for POLE testing in endometrial cancer?

Casey M Cosgrove1, David E Cohn1, Paul J Goodfellow2.   

Abstract

Entities:  

Keywords:  Endometrial cancer; Molecular classification; POLE testing

Mesh：

Substances：

Year:  2017        PMID： 28947175      PMCID： PMC5705034          DOI： 10.1016/j.ygyno.2017.09.015

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  8 in total

1.  POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.

Authors:  Bo Meng; Lien N Hoang; John B McIntyre; Máire A Duggan; Gregg S Nelson; Cheng-Han Lee; Martin Köbel
Journal:  Gynecol Oncol       Date:  2014-05-16       Impact factor: 5.482

2.  Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Authors:  Aline Talhouk; Melissa K McConechy; Samuel Leung; Winnie Yang; Amy Lum; Janine Senz; Niki Boyd; Judith Pike; Michael Anglesio; Janice S Kwon; Anthony N Karnezis; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Cancer       Date:  2017-01-06       Impact factor: 6.860

3.  Prognostic significance of POLE proofreading mutations in endometrial cancer.

Authors:  David N Church; Ellen Stelloo; Remi A Nout; Nadejda Valtcheva; Jeroen Depreeuw; Natalja ter Haar; Aurelia Noske; Frederic Amant; Ian P M Tomlinson; Peter J Wild; Diether Lambrechts; Ina M Jürgenliemk-Schulz; Jan J Jobsen; Vincent T H B M Smit; Carien L Creutzberg; Tjalling Bosse
Journal:  J Natl Cancer Inst       Date:  2014-12-12       Impact factor: 13.506

4.  Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.

Authors:  Caroline C Billingsley; David E Cohn; David G Mutch; Erinn M Hade; Paul J Goodfellow
Journal:  Int J Gynecol Cancer       Date:  2016-06       Impact factor: 3.437

5.  Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis.

Authors:  Melissa K McConechy; Aline Talhouk; Samuel Leung; Derek Chiu; Winnie Yang; Janine Senz; Linda J Reha-Krantz; Cheng-Han Lee; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Clin Cancer Res       Date:  2016-01-13       Impact factor: 12.531

6.  Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.

Authors:  Caroline C Billingsley; David E Cohn; David G Mutch; Julie A Stephens; Adrian A Suarez; Paul J Goodfellow
Journal:  Cancer       Date:  2014-09-15       Impact factor: 6.860

7.  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

Authors:  Tjalling Bosse; David N Church; Inge C van Gool; Florine A Eggink; Luke Freeman-Mills; Ellen Stelloo; Emanuele Marchi; Marco de Bruyn; Claire Palles; Remi A Nout; Cor D de Kroon; Elisabeth M Osse; Paul Klenerman; Carien L Creutzberg; Ian Pm Tomlinson; Vincent Thbm Smit; Hans W Nijman
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

8.  Integrated genomic characterization of endometrial carcinoma.

Authors:  Cyriac Kandoth; Nikolaus Schultz; Andrew D Cherniack; Rehan Akbani; Yuexin Liu; Hui Shen; A Gordon Robertson; Itai Pashtan; Ronglai Shen; Christopher C Benz; Christina Yau; Peter W Laird; Li Ding; Wei Zhang; Gordon B Mills; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine
Journal:  Nature       Date:  2013-05-02       Impact factor: 49.962
  8 in total
  2 in total

1.  Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.

Authors:  Marina Stasenko; Irina Tunnage; Charles W Ashley; Maria M Rubinstein; Alicia J Latham; Arnaud Da Cruz Paula; Jennifer J Mueller; Mario M Leitao; Claire F Friedman; Vicky Makker; Robert A Soslow; Deborah F DeLair; David M Hyman; Dimitriy Zamarin; Kaled M Alektiar; Carol A Aghajanian; Nadeem R Abu-Rustum; Britta Weigelt; Karen A Cadoo
Journal:  Gynecol Oncol       Date:  2019-11-19       Impact factor: 5.482

2.  DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer.

Authors:  Jisup Kim; Jin Kyoung Kong; Wookyeom Yang; Hanbyoul Cho; Doo Byung Chay; Bang Hyun Lee; Seong Jin Cho; Soonwon Hong; Jae-Hoon Kim
Journal:  Cancers (Basel)       Date:  2018-08-21       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.